Benjamin N Ungar, MD

Clinical Focus

• Allergic Contact Dermatitis
• Allergies
• Alopecia Areata
• Atopic Dermatitis
• Biopsy
• Contact Dermatitis
• Cryotherapy
• Dermoscopy
• Dry / Itchy Skin

Show More

• Allergic Contact Dermatitis
• Allergies
• Alopecia Areata
• Atopic Dermatitis
• Biopsy
• Contact Dermatitis
• Cryotherapy
• Dermoscopy
• Dry / Itchy Skin
• Eczema
• Freezing of Warts
• Hair Loss
• Mole Removal
• Moles
• Psoriasis
• Rash
• Rosacea
• Seborrheic Dermatitis
• Seborrheic Keratosis
• Skin Allergy
• Skin Biopsy
• Skin Cancer
• Skin Cancer Removal
• Skin Infections
• Skin Rashes

Locations

Physician Office

5E 98th St, 5th floor - Dermatology Suit, New York, NY, 10029

212-241-9728

Insurance Information

Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.

Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).

Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.

Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.

Publications

Scopus h-index:19

Article:29

Review Article:4

Comment/Debate:2

Letter:2

Recent Artifacts

• Dupilumab Improves Clinical Scores in Children and Adolescents With Moderate to Severe Atopic Dermatitis: A Real-World, Single-Center Study
• Author Correction: Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery (Nature Medicine, (2022), 28, 4, (626-629), 10.1038/s41591-022-01681-x)
• The impact of dupilumab treatment on severe acute respiratory syndrome coronavirus 2-coronavirus disease 2019 antibody responses in patients with atopic dermatitis
• Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine
• Diagnostic Efficacy Of Electrical Impedance Spectroscopy Versus Dermoscopy For Pigmented Skin Lesions: A Pilot Study
• Neoadjuvant clinical trials provide a window of opportunity for cancer drug discovery
• COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab
• Current emerging and investigational drugs for the treatment of chronic hand eczema
• Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases
• Management of Atopic Dermatitis: Clinical Utility of Ruxolitinib

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Below are financial relationships with industry reported by Dr. Ungar during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.